European Commission approves Triberzi (eluxadoline) to treat irritable bowel syndrome with diarrhoea- Allergan
The European Commission (EC) has granted marketing authorisation for Truberzi (eluxadoline) from Allergan, in Europe. Truberzi is an oral medication that offers sustained relief from multiple symptoms of irritable bowel syndrome with diarrhoea (IBS-D) in adults.With this authorisation, the drug is now approved for use in the 28 countries of the European Union, as well as in Norway, Iceland and Liechtenstein.
In two pivotal Phase III trials, Truberzi demonstrated a reduction in two symptoms of IBS-D, abdominal pain and diarrhoea. Allergan hopes to launch the new product in Europe next year.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins